To help stakeholders stay informed of the latest developments and gain insights into market trends, this article provides a systematic review and in-depth analysis of the cosmetic ingredient filings published by China’s National Medical Products Administration (NMPA) in March 2026. The report mainly covers the number of new ingredient filings during the month, basic information about the filing enterprises, the regional distribution of domestic filers, ingredients that have been filed multiple times, and interpretations of selected ingredients. It aims to offer valuable data support and information references for the cosmetics industry.

In March 2026, the Shanghai Municipal, Fujian Provincial, Hubei Provincial, and Anhui Provincial Medical Products Administrations successively issued announcements regarding cosmetic supervision and sampling inspections. A total of 12 batches of products were found to be non-compliant. This summary of the announcements aims to help enterprises stay informed of evolving regulatory trends and strengthen their quality management and compliance awareness.

On March 31, 2026, China’s National Medical Products Administration (NMPA) issued the Announcement on Matters Related to Cosmetic Registration and Filing (Draft for Comments) and is now soliciting public comments.

On March 30, 2026, China's National Medical Products Administration (NMPA) publicly solicited opinions on two mandatory national standards, including “Instructions for use of consumer interest- Part 3: General labelling for cosmetics” and “General requirements of safety and technical for toothpastes”.

Globally, the regulatory landscape for exosome cosmetics exhibits significant variability. This article systematically reviews the management measures, regulations, and ethical standards concerning exosome cosmetics in various countries/regions, including the United States, the European Union, Japan, South Korea, Taiwan, and mainland China. It explores the context of compliance and prohibitions, as well as their impact on industry development, providing comprehensive global regulatory compliance guidance for cosmetic companies.

Based on data retrieved from China’s National Medical Products Administration (NMPA), nine new cosmetic ingredients have been filed between March 13 and March 20, 2026. Detailed information is provided in the table below. At present, the associated technical specifications have not been made public, and the ingredient has not yet entered the post-filing monitoring period. As of now in 2026, a total of 49 new cosmetic ingredients have been filed.

The following FAQs are all related to ordinary cosmetics filing, CIRS Group has compiled the information and translated it into English for your reference.

In the cosmetics industry, INCI names and CAS numbers are regarded as the "birth certificates" for new ingredients. These identifiers not only establish the identity of the ingredients but also facilitate their recognition and communication in the global market. This article explores the definitions, application processes, and international market applications of INCI names and CAS numbers, aiming to help cosmetic companies better understand their significance.

Based on data retrieved from China’s National Medical Products Administration (NMPA), nine new cosmetic ingredients have been filed between March 1 and March 12, 2026. Detailed information is provided in the table below. At present, the associated technical specifications have not been made public, and the ingredient has not yet entered the post-filing monitoring period. As of now in 2026, a total of 45 new cosmetic ingredients have been filed.

Recently, the Beijing Cosmetics Review and Inspection Center has published a series of Q&A regarding ordinary cosmetics filing. The following content is primarily excerpted from the 53rd issue, compiled by CIRS Group for reference.